2-(bromomethyl)-4-methylthiazole | 913073-81-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(bromomethyl)-4-methylthiazole
• 英文别名: 2-(Bromomethyl)-4-methyl-1,3-thiazole
• CAS: 913073-81-1
• 化学式: C₅H₆BrNS
• 分子量: 192.079
• InChiKey: HAKYXXAQICRHJQ-UHFFFAOYSA-N

物化性质

• 沸点：
  216.1±23.0 °C(Predicted)
• 密度：
  1.629±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  41.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(bromomethyl)-4-methylthiazole 在 水 、 sodium 、 sodium hydride 、 氯乙酸 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 乙醇 为溶剂， 生成 5-[(4-methyl-1,3-thiazol-2-yl)methyl]-6-(4-phenylcyclohexyl)-1H-pyrimidine-2,4-dione
  参考文献：
  名称：

  Discovery of a novel non-steroidal GR antagonist with in vivo efficacy in the olanzapine-induced weight gain model in the rat

  摘要：

  We report the optimization of a series of non-steroidal GR antagonists that led to the identification of compound 7. This compound is efficacious when dosed orally in an olanzapine-induced weight gain model in rats. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.10.074

文献信息

• 4-Azaindole Derivatives
  申请人：Eisai R&D Management Co., Ltd.

  公开号：US20150094328A1

  公开（公告）日：2015-04-02

  4-Azaindole derivatives which are modulators of muscarinic acetylcholine receptor (mAChR) M1 and which may be effective for the prevention or disease modifying or symptomatic treatment of cognitive deficits associated with neurological disorders such as Alzheimer-type dementia (AD) or dementia with Lewy bodies (DLB), and a pharmaceutical composition comprising a 4-azaindole derivative as an active ingredient.

  4-氮杂吲哚衍生物是肌胆碱受体（mAChR）M1的调节剂，可能对预防或疾病修饰或症状性治疗与神经系统疾病如阿尔茨海默病（AD）或带有Lewy小体的痴呆症相关的认知缺陷有效，并且包括4-氮杂吲哚衍生物作为活性成分的药物组合物。
• [EN] 4-AZAINDOLE DERIVATIVES<br/>[FR] DÉRIVÉS DE 4-AZAINDOLE
  申请人：EISAI R&D MAN CO LTD

  公开号：WO2015049574A1

  公开（公告）日：2015-04-09

  4-Azaindole derivatives which are modulators of muscarinic acetylcholine receptor (mAChR) M1 and which may be effective for the prevention or disease modifying or symptomatic treatment of cognitive deficits associated with neurological disorders such as Alzheimer-type dementia (AD) or dementia with Lewy bodies (DLB), and a pharmaceutical composition comprising a 4-azaindole derivative as an active ingredient.

  4-氮杂吲哚衍生物是肌氨酸乙酰胆碱受体（mAChR）M1的调节剂，可能对预防或疾病修饰或症状性治疗与神经系统疾病（如阿尔茨海默病（AD）或带有Lewy小体的痴呆症（DLB））相关的认知缺陷有效，并且包括4-氮杂吲哚衍生物作为活性成分的药物组合物。
• COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF
  申请人：Ghosh Arun K.

  公开号：US20080176939A1

  公开（公告）日：2008-07-24

  The present invention provides novel beta-secretase inhibitors and methods for their use, including methods of treating Alzheimer's disease.

  本发明提供了一种新颖的β-分泌酶抑制剂及其使用方法，包括治疗阿尔茨海默病的方法。
• Compounds Which Inhibit Beta-Secretase Activity and Methods of Use
  申请人：Ghosh K. Arun

  公开号：US20070117793A1

  公开（公告）日：2007-05-24

  The present invention provides novel beta-secretase inhibitors and methods for their use, including methods of treating Alzheimer's disease.

  本发明提供了新型β-分泌酶抑制剂及其使用方法，包括治疗阿尔茨海默病的方法。
• Compounds which inhibit beta-secretase activity and methods of use
  申请人：CoMentis, Inc.

  公开号：US07504420B2

  公开（公告）日：2009-03-17

  The present invention provides novel beta-secretase inhibitors and methods for their use, including methods of treating Alzheimer's disease.

  本发明提供了新型β-分泌酶抑制剂及其使用方法，包括用于治疗阿尔茨海默病的方法。